HAIFA, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it intends, subject to market and other conditions, to offer shares of its common stock and warrants to purchase shares of its common stock in a registered public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. Pluristem also intends to grant the underwriters of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Pluristem plans to use the proceeds from the offering to conduct clinical trials, research and product development activities and for general corporate purposes, including general working capital purposes. Jefferies & Company, Inc. is acting as sole book-running manager for the proposed offering. Oppenheimer & Co. Inc. is acting as co-lead manager for the proposed offering. Needham & Company, LLC and Maxim Group LLC are acting as co-managers for the proposed offering. In addition, Leader Capital Markets Ltd. is acting as the company's financial advisor in connection with the proposed offering.
The securities described above are being offered by Pluristem pursuant to a "shelf" registration statement previously declared effective by the Securities and Exchange Commission (SEC) on October 20, 2011 (File No. 333-177009). A prospectus supplement and an accompanying prospectus will be filed with the SEC in connection with the offering. Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration statement, and the other documents that Pluristem has filed with the SEC for more complete information about Pluristem and this offering. Once filed, copies of the prospectus supplement and accompanying prospectus relating to these securities may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com. Investors may also obtain these documents for no charge by visiting the SEC's website at www.sec.gov .
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV